The measurement of high-sensitivity C-reactive protein (hs-CRP) using a high-sensitivity (hs) assay had a predicted impaired LVEF with 92.9% sensitivity and 45.7% specificity in breast cancer patients (Onitilo et al., 2012). The gene discussed is CRP; the disease is breast cancer.